Teradyne Stock Drops 19.4% Despite Q1 Earnings Beat

Teradyne's Q1 2026 results appeared nearly flawless on paper: revenue surged 87% year-over-year to $1.28 billion, and non-GAAP EPS of $2.56 beat analyst estimates of $2.04 by 25% . Gross margins reached 60.9% — up 370 basis points sequentially. Yet the stock fell 19.4%, as investors focused not on Q1's strength but on the sequential step-down embedded in Q2 guidance.

The issue centers on margin normalization and revenue concentration. Approximately 70% of Q1 revenue was AI-driven, a level that created a high comparison base against which Q2's guided revenue of $1.15–$1.25 billion — a sequential decline — looks disappointing. Gross margins are expected to compress to 58–59% in Q2 as one-time operational tailwinds that inflated Q1 results fade. Customer concentration and fab build-out timing added additional uncertainty to the second-half revenue outlook .

JP Morgan and other analysts maintained buy ratings on TER, with full-year targets of $6 billion in revenue and $9.50–$11.00 non-GAAP EPS unchanged. The market's reaction reflects a recurring risk in high-growth semiconductor testing stocks: when a single strong quarter is followed by guidance that implies normalization, investors discount the beat and price in the deceleration. The underlying AI-driven semiconductor testing demand thesis remains intact, but near-term execution visibility has narrowed.

Related Stocks

• TER